Optimal dilutions for each application to be determined by the researcher.
Figure 1 Immunohistochemistry Validation of SARS-CoV-2 (COVID-19) Nucleocapsid in COVID-19 Patient Lung Immunohistochemical analysis of paraffin-embedded COVID-19 patient lung tissue using anti- SARS-CoV-2 (COVID-19) Nucleocapsid antibody (10-353, 1 ug/mL). Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT, antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4&730,C. A goat anti-rabbit IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin. Strong signal of SARS-COV-2 Nucleocapsid protein was observed in the macrophages of COVID-19 patient lung, but not in non-COVID-19 patient lung.
Figure 2 Sandwich ELISA for SARS-CoV-2 (COVID-19) Matched Pair Nucleocapsid AntibodiesAntibodies: SARS-CoV-2 (COVID-19) Nucleocapsid Antibodies, 35-720 and 10-353. A sandwich ELISA was performed using SARS-CoV-2 Nucleocapsid antibody (35-720, 2ug/ml) as capture antibody, the Nucleocapsid recombinant protein as the binding protein (10-306), and the anti-SARS-CoV-2 Nucleocapsid antibody (10-353, 0.1ug/ml) as the detection antibody. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:20000 dilution. Detection range is from 0.03 ng to 300 ng. EC50 = 6.9 ng
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
